Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Raised to $33.00 at Needham & Company LLC

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price target raised by Needham & Company LLC from $30.00 to $33.00 in a research report sent to investors on Wednesday, Marketbeat.com reports. Needham & Company LLC currently has a buy rating on the stock.

Several other equities analysts have also recently weighed in on DAWN. JPMorgan Chase & Co. raised their price objective on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an overweight rating in a research note on Monday. The Goldman Sachs Group decreased their target price on Day One Biopharmaceuticals from $50.00 to $44.00 and set a buy rating for the company in a research report on Tuesday, February 27th. Piper Sandler reaffirmed an overweight rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. Finally, Oppenheimer reaffirmed a market perform rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of Moderate Buy and an average price target of $39.33.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ:DAWN opened at $15.19 on Wednesday. The stock’s fifty day simple moving average is $15.28 and its two-hundred day simple moving average is $13.79. Day One Biopharmaceuticals has a 1-year low of $9.67 and a 1-year high of $17.85.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings data on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.07). As a group, research analysts expect that Day One Biopharmaceuticals will post -2.66 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Samuel C. Blackman sold 2,258 shares of Day One Biopharmaceuticals stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the sale, the insider now owns 1,244,662 shares of the company’s stock, valued at approximately $18,981,095.50. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CEO Jeremy Bender sold 7,615 shares of Day One Biopharmaceuticals stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $116,128.75. Following the completion of the sale, the chief executive officer now owns 721,813 shares of the company’s stock, valued at approximately $11,007,648.25. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Samuel C. Blackman sold 2,258 shares of Day One Biopharmaceuticals stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the sale, the insider now directly owns 1,244,662 shares of the company’s stock, valued at approximately $18,981,095.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 55,781 shares of company stock valued at $883,160. 8.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Day One Biopharmaceuticals by 8.1% during the 3rd quarter. Vanguard Group Inc. now owns 4,629,754 shares of the company’s stock valued at $56,807,000 after buying an additional 346,090 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Day One Biopharmaceuticals by 38.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 447,138 shares of the company’s stock valued at $5,486,000 after buying an additional 125,050 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Day One Biopharmaceuticals by 22.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company’s stock valued at $2,703,000 after buying an additional 40,387 shares in the last quarter. TimesSquare Capital Management LLC boosted its position in shares of Day One Biopharmaceuticals by 41.8% during the 3rd quarter. TimesSquare Capital Management LLC now owns 1,142,610 shares of the company’s stock valued at $14,020,000 after acquiring an additional 336,910 shares during the last quarter. Finally, Deutsche Bank AG grew its holdings in shares of Day One Biopharmaceuticals by 5.5% during the third quarter. Deutsche Bank AG now owns 177,137 shares of the company’s stock worth $2,173,000 after purchasing an additional 9,219 shares in the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.